Vertex Pharmaceuticals Incorporated announced that inaxaplin (VX 147) has advanced into the Phase III portion of the global Phase II/III pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care
Lumicell, Inc., announced the FDA approved the company’s New Drug Application (NDA) for its Lumisight (pegulicianine) optical imaging agent and its Premarket Approval (PMA) application for Lumicell Direct Visualization System (DVS), together referred to as LumiSystem